Wakefield Health
Call 04 381 8100
Financial information

Five year financial summary

  Year ended / as at 31 March
$000 except per share amounts 2007 2008 2009 2010
2011
Revenue from continuing operations  -  Note 1 64,482 78,022 86,075 76,803 75,872
EBITDA 15,008 18,721 22,070 16,316 14,784
EBIT 9,859 13,384 16,434 9,726 8,173
Net profit from continuing operations 5,434 7,925 10,133 6,196 582
Net profit from discontinued operations  -  Note 2 (1,610) (757) - - -
Reported net profit after tax 3,824 7,168 10,133 6,196 582
Adjusted net profit after tax - Note 3
5,520
7,914
10,435
6,145
5,127






Adjusted earnings per share from continuing operations (cents) 39 56 74 43 36
Dividends per share (cents) 17 20 25 18 16
           
Total assets 103,697 110,752 124,196 126,947 123,526
Total equity 69,313 79,561 91,556 96,448 88,432
Net tangible assets per share ($) 3.32 4.10 4.86 5.14 4.62
           
Cash flows from operating activities 9,809 12,934 19,245 12,584 12,042
Capital expenditure  -  Note 4
5,827 4,135 6,507 9,434 17,594

 


1- 2008, 2009, 2010 and 2011 revenues are stated inclusive of the full value of ACC and DHB contracts, whereas 2007 revenues are shown net of payments to specialists under these contracts reflecting the accounting presentation that was applied at that time.
2- Represents the results of P3 Research Limited, which was sold in August 2007.
3- Adjusted net profit after tax excludes adjustments to deferred tax in the 2011 financial year for changes in tax legislation of $4.3m, revaluation of interest rate swaps (net of tax effect) and discontinued operations.
4- Represents payments for the purchase of property, plant and equipment plus payments for the purchase of software.